WASHINGTON, DC / BERN, SWITZERLAND - Children’s National Hospital and Compremium AG entered into a strategic partnership to develop and commercialize cutting-edge medical technologies for the pediatric population. This partnership will bring Compremium’s non-invasive and AI-enhanced technology to the forefront of pediatric healthcare.
Diagnosing pressure-related conditions without complicated, invasive procedures has long been a challenge in the medical community. Compremium’s technology aims to transform the diagnosis of pressure physiologies, including venous pressure, intracranial pressure, and tissue pressure conditions with their non-invasive, point of care solution. Through this strategic collaboration, Children’s National will serve as the Pediatric Innovation Hub for Compremium, leading clinical studies, research projects, and commercialization efforts focused on non-invasive pressure monitoring and other breakthrough technologies.
“This partnership is a pivotal step in advancing pediatric-specific technologies to address critical gaps in care,” said Kolaleh Eskandanian, Ph.D., M.B.A., vice president and chief innovation officer at Children’s National. “Compremium’s non-invasive, real-time pressure monitoring technology not only has the potential to transform pediatric care but also demonstrates how prioritizing pediatric innovation can pave the way for broader adoption and scalability to adult populations.”
Initial area of focus will be the use of Compremium’s technology in congenital heart disease (CHD) patients. Pediatric cardiologists require frequent, non-invasive monitoring of central venous pressure (CVP), a crucial measure of blood volume returning to the heart and overall circulatory function. Improved CVP data could provide new insights into cardiovascular health, potentially leading to better interventions and preventing long-term complications such as developmental delays and learning difficulties, which affect approximately 33% of CHD patients nationwide.
“Non-invasive CVP monitoring for the pediatric population is the holy grail of cardiac care, a long-awaited advancement that has the potential to revolutionize care. Pediatric cardiac surgeons worldwide are eager for this breakthrough solution, which could transform how we monitor and treat cardiovascular patients. It’s exciting to see this innovation, and we are thrilled that Children’s National is leading the way in bringing it to children everywhere.”
Yves d'Udekem, M.D., Ph.D., division chief of Cardiac Surgery and co-director of the Children's National Heart Center
For Compremium, this partnership marks an important milestone—its first major initiative in pediatric healthcare. “We are honored to collaborate with Children’s National Hospital,” said Vincent Baumann, CEO of Compremium AG. “This initiative allows us to accelerate and expand the clinical adoption of our solution, particularly for a vulnerable patient population.”
“By integrating Compremium’s cutting-edge technology with AI-driven advancements, we aim to enhance accuracy, enable real-time data analysis, and provide predictive insights—critical capabilities for improving pediatric care” said Eskandanian. “Our pediatric providers are eager for innovative, child-friendly monitoring solutions that reduce the need for invasive procedures, and this collaboration is dedicated to making that a reality.”
For more information, follow us on LinkedIn or contact us:
USA: Aswin Bhuvanendran, This email address is being protected from spambots. You need JavaScript enabled to view it., +1 301 617 89 84
Switzerland/Europe: Vincent Baumann, This email address is being protected from spambots. You need JavaScript enabled to view it., +41 79 933 96 48
About Compremium AG
Compremium is a Swiss medicaldevice company from Bern, Switzerland innovating in the diagnosis of pressure conditionsin the human body. Compremium’s proprietary technology of combining ultrasoundand pressure sensing was pioneered by Dr. Ulrich Baumann. In 2020, the companywas founded by Vincent Baumann and private investors to bring this breakthroughtechnology to the market. The technology has been proven in over 40 clinicalstudies and has the potential to aid in diagnosing more than 30 medicalindications and expects to make a significant impact in the diagnosis of anumber of medical conditions. The lead indication for diagnosis of tissuerelated conditions is 510K-cleared by the FDA as of April 2023 and Compremiumsubmits additional FDA and CE submissions in 2025. A prototype of the devicehas been in use by NASA on the International Space Station (ISS) for eightyears.
About Children’s National Hospital
Children’s National Hospital,based in Washington, D.C., was established in 1870 to help every child grow upstronger. Today, it is one of the top 10 children’s hospitals in the nation andranked in all specialties evaluated by U.S. News & World Report. Children’sNational is transforming pediatric medicine for all children. The Children’sNational Research & Innovation Campus opened in 2021, a first-of-its-kindpediatric hub dedicated to developing new and better ways to care for kids.Children’s National has been designated three times in a row as a Magnet®hospital, demonstrating the highest standards of nursing and patient caredelivery. This pediatric academic health system offers expert care through aconvenient, community-based primary care network and specialty care locationsin the D.C. metropolitan area, including Maryland and Virginia. Children’sNational is home to the Children’s NationalResearch Institute and Sheikh Zayed Institutefor Pediatric Surgical Innovation. It is recognized for its expertise and innovation in pediatric careand as a strong voice for children through advocacy at the local, regional andnational levels. As a nonprofit, Children's National relies on generous donorsto help ensure that every child receives the care they need.